Fever in the returned traveller: the utility of the Platelia Dengue NS1 antigen enzyme immunoassay for the diagnosis of dengue in a non-endemic setting.


Journal

Pathology
ISSN: 1465-3931
Titre abrégé: Pathology
Pays: England
ID NLM: 0175411

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 16 09 2019
revised: 19 01 2020
accepted: 23 01 2020
pubmed: 29 2 2020
medline: 15 12 2020
entrez: 29 2 2020
Statut: ppublish

Résumé

Investigating fever in the returned traveller can be difficult and costly. Dengue is one of the most frequently reported aetiologies. NS1 is a non-structural dengue virus protein detectable during acute infection. The aim of this report is to describe the utility of the Platelia Dengue NS1 antigen enzyme immunoassay (EIA) for detection of dengue in a non-endemic region compared to a composite gold standard of contemporaneous molecular testing and seroconversion. We performed a retrospective analysis of all dengue serology tests from 6 February 2012 to 5 December 2018. Dengue serology and in-house flavivirus molecular results were identified using the laboratory information management system. Dengue serology was performed using the Bio-Rad Platelia Dengue NS1 antigen EIA, and Abbott Panbio Dengue IgG and IgM EIA. True positive NS1 result was defined as positive molecular test within one week of the positive NS1 result or seroconversion within 120 days. NS1 negative samples that remained negative to all dengue markers on repeat more than 10 and up to 120 days after were labelled as true negatives. More than 75% of cases had a serology pattern consistent with primary dengue. Sensitivity and specificity of NS1 Ag EIA was 96.4% (95% CI 92.3-98.7%) and 98.4% (95% CI 94.5-99.8%), respectively. Performance was poorer in serotype 4 infections (sensitivity 50%). Platelia Dengue NS1 antigen EIA test performance in the returned traveller cohort fulfils the remit as a single diagnostic test for acute dengue infection.

Identifiants

pubmed: 32107080
pii: S0031-3025(20)30464-5
doi: 10.1016/j.pathol.2020.01.438
pii:
doi:

Substances chimiques

Antibodies, Viral 0
Viral Nonstructural Proteins 0
Viral Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

370-372

Informations de copyright

Copyright © 2020 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.

Auteurs

David A Foley (DA)

Victorian Infectious Diseases Reference Laboratory, Parkville, Vic, Australia; Department of Infectious Diseases, Perth Children's Hospital, Nedlands, WA, Australia. Electronic address: drdavidanthonyfoley@gmail.com.

Daniel K Yeoh (DK)

Department of Infectious Diseases, Perth Children's Hospital, Nedlands, WA, Australia.

Theo Karapanagiotidis (T)

Victorian Infectious Diseases Reference Laboratory, Parkville, Vic, Australia.

Tinashe Nhindri (T)

Victorian Infectious Diseases Reference Laboratory, Parkville, Vic, Australia.

Mike Catton (M)

Victorian Infectious Diseases Reference Laboratory, Parkville, Vic, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH